Shashwat Singh

So I had two set of questions. First one was that excluding the ibuprofen business, the base business delivered a 24% growth on this quarter. Could you highlight the key driver behind this performance? And do you believe this growth trajectory will be sustainable going ahead?

Okay. My next question would be looking solely at the base business. What would we consider to be a sustainable revenue growth, like you said, was 10%. So will that be for next 5 years easily? And what would be the range for EBITDA margins going ahead?

And sir, what about the margin front?